Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

NCT05617040 is registered in ClinicalTrials.gov with Barinthus Biotherapeutics as lead sponsor.

NCT NCT05617040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05617040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Lead sponsor
Barinthus Biotherapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
January 30, 2023
Completion date
February 5, 2025
Enrollment
22 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer